このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

機能的 MRI 研究のための認知タスクの開発と実装

2026年11月4日 更新者:National Institute on Drug Abuse (NIDA)

Background:

  • Drugs of abuse have effects on mood, behavior, thinking, and decision making that may encourage people to continue using them and make it difficult for them to stop. Researchers who study these effects are interested in developing new tests to evaluate how drugs and drug use affect different areas of the brain.
  • Magnetic resonance imaging (MRI) scans allow researchers to study brain activity and changes to brain function. When specific psychological tests are performed during functional MRI (fMRI) scans, researchers can examine the effects of drug use on the brain. By developing and testing new procedures for fMRI studies, more information can be obtained on brain function and activity in drug-using and non-drug-using individuals, and this information can help develop new treatments and therapies for substance abuse.

Objectives:

- To develop, assess and refine of cognitive and affective tasks and determination of their practical feasibility and efficacy for both MRI and non-MRI application.

Eligibility:

  • Healthy volunteers between 18 and 65 years of age who are willing to undergo MRI scanning.
  • Both drug-using and non-drug-using individuals will be selected for this study.

Design:

  • Before the start of the study, participants may complete as assessment of medical and psychological history, and provide information about past or current drug use. Researchers will introduce the tasks to be performed and may have participants practice the tasks.
  • During the study, participants will be asked to do one or more tasks selected by the researchers. The tasks may be performed on a computer in an MRI machine, and may involve receiving rewards (such as money or sips of juice) for actions, memory and reaction-time tests, or other tests that involve responding to instructions on the screen.
  • Participants will receive compensation for their participation in the study, including hourly compensation for individual visits.

調査の概要

状態

完了

詳細な説明

Objective: Drugs of abuse have cognitive and affective effects that may contribute to the inception and maintenance of their use. In order to measure these effects, psychological tests suitable for use both in and outside the fMRI scanner need to be developed and validated. Thus, the objective of this protocol is to allow for the development, assessment and refinement of cognitive and affective tasks and determination of their practical feasibility and efficacy for both MRI and non-MRI application.

Study Population: This minimal-risk protocol will employ volunteer participants aged 18-65, who must be generally healthy. In order to ensure applicability to relevant groups, both drug and nondrug using volunteers as well as those recruited from clinical populations will be used to validate task design and parameters.

Design: Participants may pilot tasks outside and/or inside the MRI scanner, depending on the aspects of task development requiring verification. Tasks developed de novo will undergo both steps. Modifications to previously published MRI tasks may require only one of the steps. Upon their successful verification, specific experimental manipulations will be performed under separate, hypothesis driven protocols.

Outcome measures: Our goal is to determine if the tasks developed reliably and appropriately measure specific cognitive constructs and behaviors thought to be associated with specific brain systems, if they yield measurable and interpretable fMRI results.

研究の種類

観察的

入学 (実際)

525

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • Maryland
      • Baltimore、Maryland、アメリカ、21224
        • National Institute on Drug Abuse, Biomedical Research Center (BRC)

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年~65年 (大人、高齢者)

健康ボランティアの受け入れ

はい

受講資格のある性別

全て

サンプリング方法

非確率サンプル

調査対象母集団

Subjects must be between the ages of 18-65 and be generally healthy. (Please note that references to adults in this protocol refers to those age 18 and older). Depending on the task being developed and specific task goals, they may have a substance use disorder or have no history of substance use.

説明

  • INCLUSION CRITERIA:

Bench Only Phase (no MRI)

Participants will be considered for one of three categories: 379-bench-control, 379-bench-smoker/vaper, 379-bench-user. Vapers will be admitted to experiments involving smoking cues (with cues specific to vaping) because it has been shown that responses to vaping cues are very similar to responses to smoking cues and can be lumped together in analyses.

Participant must meet the following inclusion criteria for the Bench Only Phase:

  1. Between the ages of 18-65.

  2. All subjects must be able to provide informed consent/assent.

  3. Additional criteria for specific populations:

    1. 379-bench-smoker/vaper: regular smoker of tobacco cigarettes or nicotine vaper with a urine cotinine level corresponding to nicotine user status for the specific test being used (typically corresponding to a urine cotinine above about 200 ng/ml) and have been smoking or vaping consistently for at least one year (excluding quit attempts)
    2. 379-bench-user: DSM-V substance use disorder on a substance other than nicotine.

EXCLUSION CRITERIA:

Bench Only Phase (Does not require MRI. Task requires gathering of accurate behavioral data).

  1. History of neurologic injury including but not limited to CVA, CNS tumor, or head trauma with persistent sequelae. Assessment tool: pre-screen survey and medical history.

    Rationale: Neurologic injury is likely to impair performance on the range of tasks to be piloted under this protocol.

  2. Current use of psychoactive medications likely to affect the performance of the task under consideration, unless required for the psychiatric disorder for which participants in the 379-user and 379-other-psych-diagnosis subcategories are being treated. Assessment tool: pre-screen survey, medical history. Rationale: certain psychoactive medications may alter performance on the range of tasks to be piloted under this protocol.

  3. Cognitive impairment. Assessment tool: self report of extended placement in special education classes for learning problems, history of specific learning disability or mental retardation. Rationale: Cognitive impairment is likely to impair performance on the range of tasks to be piloted under this protocol and may impair ability to tolerate the procedures.

  4. Current major mood, anxiety or psychotic disorder with symptoms severe enough to impair ability to participate (unless task is being evaluated in a specific clinical population). Assessment tool: self report, medical history. Rationale: Current major mood or psychotic disorders with poorly controlled symptoms may impair performance on the range of tasks to be piloted under this protocol and may impair ability to tolerate the procedures.

  5. Non-English speaking. Assessment tool(s): self-report. Rationale: To include non-English speakers, we would have to translate the consent and other study documents and hire and train bilingual staff, which would require resources that we do not have and could not justify given the small sample size for each experiment. Additionally, the data integrity of some of the cognitive tasks and standardized questionnaires used in this study would be compromised as they have only been validated in English. Most importantly, ongoing communication regarding safety procedures is necessary when participants are undergoing study procedures. The inability to effectively communicate safety procedures in a language other than English could compromise the safety of non-English speaking participants.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 観測モデル:CASE_CONTROL
  • 時間の展望:CROSS_SECTIONAL

コホートと介入

グループ/コホート
379-bench-control

healthy control who will only do behavioral tasks

379-bench-other-psych-diagnosis

someone with a DSM-V disorder, stable and in treatment (i.e., no medication changes in the previous four weeks and a clearly identified treating psychiatrist) who will only do behavioral tasks

379-bench-smoker

daily smoker of tobacco cigarettes for at least one year (excluding quit attempts) who will only do behavioral tasks

379-bench-user

someone with a DSM-V substance use disorder on a substance other than nicotine who will only do behavioral tasks

379-control

healthy control who can do MRI

379-other-psych -diagnosis

someone with a DSM-V disorder, stable and in treatment (i.e., no medication changes in the previous four weeks and a clearly identified treating psychiatrist) who can do MRI

379-smoker

daily smoker of tobacco cigarettes for at least one year (excluding quit attempts) who can do MRI

379-user

someone with a DSM-V substance use disorder on a substance other than nicotine who can do MRI

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
To determine if the tasks reliably and appropriately measure specific cognitive constructs and behaviors thought to be associated with specific brain systems and, also if they yield measurable and interpretable fMRI results.
時間枠:each visit

1. To derive the parameters necessary to determine the reliability and validity of cognitive tasks.2. To determine the ability of various control and target populations to perform the tasks appropriately in and out of the MRI scanner.3. To determine the task parameters optimal for the activation of specific brain regions when employed during fMRI scanning.

each visit

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

捜査官

  • 主任研究者:Thomas J Ross, Ph.D.、National Institute on Drug Abuse (NIDA)

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2005年5月22日

試験登録日

最初に提出

2009年12月18日

QC基準を満たした最初の提出物

2009年12月18日

最初の投稿 (推定)

2009年12月21日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月5日

QC基準を満たした最後の更新が送信されました

2026年11月4日

最終確認日

2026年6月11日

詳しくは

本研究に関する用語

その他の研究ID番号

  • 999903379
  • 03-DA-N379

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

IPD プランの説明

There is no plan to share raw data from the study as this is a task development protocol in which the objective is the development, assessment and refinement of cognitive and affective tasks and determination of their practical feasibility and efficacy for both MRI and non-MRI application for future protocols.

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する